Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Atrial FibrillationHeart, Artery and Coronary Diseases

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial

JAMA Cardiol

Yamaguchi J, Arashi H, Hagiwara N, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Matsui K, Ogawa H, AFIRE Investigators

doi: 10.1001/jamacardio.2025.2611

Heart Failure

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1001/jamacardio.2025.0848

Atrial Fibrillation

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

JAMA Cardiol

Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, Steffel J, Russo AM, van Gelder IC, Ferdinand KC, Lopes RD, Mundl H, Benczur B, Gómez-Doblas JJ, Glikson M, Goudev A, Grove EL, Halvorsen S, Kiviniemi T, Martin AC, Sandhu RK, Vinereanu D, Rockhold FW, Caso V, Coppolecchia R, Patel MR

doi: 10.1001/jamacardio.2025.0277

Further Publications

Early Restrictive vs Liberal Oxygen for Trauma Patients: The TRAUMOX2 Randomized Clinical Trial

JAMA

Arleth T, Baekgaard J, Siersma V, Creutzburg A, Dinesen F, Rosenkrantz O, Heiberg J, Isbye D, Mikkelsen S, Hansen PM, Zwisler ST, Darling S, Petersen LB, Mørkeberg MCR, Andersen M, Fenger-Eriksen C, Bach PT, Van Vledder MG, Van Lieshout EMM, Ottenhof NA, Maissan IM, Den Hartog D, Hautz WE, Jakob DA, Iten M, Haenggi M, Albrecht R, Hinkelbein J, Klimek M, Rasmussen LS, Steinmetz J, TRAUMOX2 Trial Group

doi: 10.1001/jama.2024.25786

Atrial FibrillationTherapy and Intervention

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

JAMA Cardiol

Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT

doi: 10.1001/jamacardio.2025.3393

Myocardial Infarction

Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients

Atherosclerosis

Rivero-Santana B, Saldaña-García J, Jurado-Román A, Cantolla-Pablo P, Gil-Fernández M, López-Sendón J, Tardif JC, Moreno R, Fernández-Velasco M

doi: 10.1016/j.atherosclerosis.2025.120443

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart Failure

Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial

JAMA Cardiol

Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, Connors JM, Jorde UP, Zimpfer D, Pya Y, Conway J, Anyanwu A, Scandroglio AM, Sulemanjee N, Atluri P, Keebler M, Selzman CH, Alexis JD, Hayward C, Henderson J, Dirckx N, Gazzola C, Mehra MR, ARIES Investigators

doi: 10.1001/jamacardio.2024.4849

Related content

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Early Restrictive vs Liberal Oxygen for Trauma Patients: The TRAUMOX2 Randomized Clinical Trial

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial